Skip to content
Screener

Dianthus Therapeutics DNTH Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$53.01M-34.3%
Vor Biopharma logo
Vor BiopharmaVOR
-$220.33M-578%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$15.22M-22.1%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$74.73M-31.5%
Alumis Inc. logo
Alumis Inc.ALMS
-$93.71M+5.4%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
-$14M+31.8%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.09B+902%
Enterprise value$5.47B+817%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net loss per share attributable to common stockholders, basic and diluted$(0.85)$(0.82)
Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted48,032,74235,790,700
Comprehensive loss:
Net loss$(40,834)$(29,511)
Other comprehensive (loss)/income:
Unrealized (loss)/gain on marketable securities(1,064)164
Total other comprehensive (loss)/income(1,064)164
Total comprehensive loss$(41,898)$(29,347)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Dianthus Therapeutics (DNTH) reported comprehensive income (loss), net of tax, attributable to parent of -$41.9M in Q1 2026.
How has Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 42.8% year-over-year, from -$29.35M to -$41.9M.
What is the long-term trend for Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Over 3 years (2021 to 2024), Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 6.1% compound annual growth rate (CAGR), from -$71.14M to -$84.91M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric measures the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a comprehensive view of the company's financial health by including items that bypass the traditional income statement. This figure is essential for understanding the total economic impact of all financial activities on shareholder value.

Ask your AI about Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude